Free Trial
NASDAQ:CING

Cingulate Q1 2025 Earnings Report

Cingulate logo
$4.05 -0.05 (-1.22%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$4.06 +0.00 (+0.12%)
As of 06/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate EPS Results

Actual EPS
-$1.04
Consensus EPS
-$1.00
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Cingulate's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cingulate Earnings Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Cingulate receives FDA meeting feedback on ADHD drug
CING: First Quarter 2025 Results
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile

More Earnings Resources from MarketBeat